Results 101 to 110 of about 2,487 (198)

Analysis of Beyfortus^® (Nirsevimab) Immunization Campaign: Effectiveness, Biases, and ADE Risks in RSV Prevention

Current Issues in Molecular Biology
Respiratory infections with respiratory syncytial virus (RSV) account for an important part of hospital admissions for acute respiratory infections. Nirsevimab has been developed to reduce the hospital burden of RSV infections.
Hélène Banoun
doaj   +1 more source

Nirsevimab Administration and RSV Hospitalization in the 2024-2025 Season

JAMA Network Open
This cohort study examines rates of hospitalization associated with respiratory syncytial virus (RSV) among infants by nirsevimab administration during the 2024-2025 season.
Pelletier, Jonathan H., Rush, Sarah Z., Robinette, Eric, Maholtz, Danielle E., Bigham, Michael T., Forbes, Michael L., Shein, Steven L., Karsies, Todd J., Horvat, Christopher M.   +8 more
openaire   +2 more sources

Cost-savings and health impact of strategies for prevention of Respiratory Syncytial Virus with nirsevimab in Chile based on the integrated analysis of 2019-2023 national databases: A retrospective study.

Journal of Infection and Public Health
BACKGROUND In the latter half of 2023, the northern hemisphere initiated the rollout of nirsevimab immunization strategies for infants, yielding promising early results. As Chile prepared for its 2024 strategy implementation, we retrospectively evaluated
Denis Sauré, Miguel O'Ryan, J. P. Torres, Natalia Trigo, Gonzalo Díaz, M. Goic, Charles Thraves, Jorge Pacheco, Patricio Aguilera, A. Caro, Leonardo J. Basso   +10 more
semanticscholar   +1 more source

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Frontiers in Public Health
BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes
Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster   +8 more
doaj   +1 more source

Nirsevimab Treatment of RSV Bronchiolitis in Pediatric Emergency Departments

JAMA Network Open
Importance New resistant mutations of respiratory syncytial virus type B (RSV-B) have been observed during the first year of implementation nirsevimab treatment. During the second season of implementation of nirsevimab treatment in France, RSV-B was predominant.
Lenglart, Lea, Levy, Corinne, Basmaci, Romain, Levieux, Karine, Kramer, Rolf, de Mari, Pauline, Béchet, Stéphane, Launay, Elise, Perceval, Lise, Cohen, Laure, Aupiais, Camille, de Pontual, Loic, Rybak, Alexis, Ouldali, Naim, Cohen, Robert   +14 more
openaire   +3 more sources

How a major discovery can become a public health failure when used subotptimally: lessons from early nirsevimab implementation

Italian Journal of Pediatrics
Background In this Debate, based on our clinical data from the “pre-nirsevimab” and “first year of nirsevimab implementation” bronchiolitis seasons, we challenge the validity of policy decisions that led to partial immunization coverage of eligible ...
Danilo Buonsenso, Aida Perramon-Malavez, Rosa Morello, Carolina Gentili, Marta Bellorofonte, Antoni Soriano-Arandes   +5 more
doaj   +1 more source

A single-center observational study of nirsevimab for prevention of RSV infection in preterm infants

Frontiers in Pediatrics
ObjectiveThis study aims to evaluate the clinical efficacy of nirsevimab in preventing respiratory syncytial virus (RSV) infection in preterm infants, highlighting its potential to improve neonatal respiratory health.MethodsWe conducted a retrospective ...
Rina Su, Rigonggaowa A, Fang Yao, Yanbin An, Cheng Cai, Lei Yun   +5 more
doaj   +1 more source

Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: early real-world data from Tuscany (Italy) in the 2024–25 RSV season

European Journal of Pediatrics
Real-world evidence on the public health impact of nirsevimab across a full RSV season in Italy is currently lacking, particularly with respect to hospitalisations and admissions to paediatric intensive care units (PICU), and only limited data are ...
F. Nieddu, Marina Vignoli, E. Ferraro, S. Boscia, V. Astorino, C. Pelosi, V. Guarnieri, Francesca Quaranta, Vanessa Perone, Paolo Biasci, L. Lodi, S. Ricci, Carlo Dani, Giuseppe Indolfi, P. Bourron, S. Parisi, C. Azzari, M. Moriondo   +17 more
semanticscholar   +1 more source

Estimating the Public Health and Economic Impact of Immunisation with Nirsevimab or Maternal Immunisation for the Prevention of RSV-Related Outcomes Over Infants’ First RSV Season in the UK

Infectious Diseases and Therapy
Introduction Respiratory syncytial virus (RSV) poses a significant health burden on infants, particularly during their first RSV season. Immunoprophylactic strategies, such as the administration of nirsevimab, a long-acting monoclonal antibody, have been
Mersha Chetty, Paul Costello, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +4 more
doaj   +1 more source

Respiratory syncytial virus immunization with nirsevimab: Acceptance and satisfaction assessment in infants and risk groups in the region of Murcia (Spain)

Human Vaccines & Immunotherapeutics
Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants under two years of age, often resulting in bronchiolitis and pneumonia, which contribute to high hospitalization rates.
Jaime Jesús Pérez Martín, María de la Cruz Gómez Moreno, Susana Sánchez Manresa, María Del Pilar Ros Abellán, M. Zornoza-Moreno   +4 more
semanticscholar   +1 more source